KR20250169356A - 인터류킨-2 제제의 사용 방법 - Google Patents
인터류킨-2 제제의 사용 방법Info
- Publication number
- KR20250169356A KR20250169356A KR1020247021478A KR20247021478A KR20250169356A KR 20250169356 A KR20250169356 A KR 20250169356A KR 1020247021478 A KR1020247021478 A KR 1020247021478A KR 20247021478 A KR20247021478 A KR 20247021478A KR 20250169356 A KR20250169356 A KR 20250169356A
- Authority
- KR
- South Korea
- Prior art keywords
- amino acid
- fold
- seq
- fusion protein
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Transplantation (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163284978P | 2021-12-01 | 2021-12-01 | |
| US63/284,978 | 2021-12-01 | ||
| US202263348201P | 2022-06-02 | 2022-06-02 | |
| US63/348,201 | 2022-06-02 | ||
| PCT/US2022/080728 WO2023102463A1 (en) | 2021-12-01 | 2022-12-01 | Methods of using interleukin-2 agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20250169356A true KR20250169356A (ko) | 2025-12-03 |
Family
ID=84981477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247021478A Pending KR20250169356A (ko) | 2021-12-01 | 2022-12-01 | 인터류킨-2 제제의 사용 방법 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12642840B2 (enExample) |
| EP (1) | EP4440598A1 (enExample) |
| JP (1) | JP2024543209A (enExample) |
| KR (1) | KR20250169356A (enExample) |
| CN (1) | CN120131911A (enExample) |
| AU (1) | AU2022399832A1 (enExample) |
| CA (1) | CA3238574A1 (enExample) |
| MX (1) | MX2024006746A (enExample) |
| TW (1) | TW202333772A (enExample) |
| WO (1) | WO2023102463A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12022550165A1 (en) | 2019-07-26 | 2023-05-08 | Visterra Inc | Interleukin-2 agents and uses thereof |
| CA3203977A1 (en) | 2020-12-04 | 2022-06-09 | Visterra, Inc. | Methods of using interleukin-2 agents |
| TW202333772A (zh) | 2021-12-01 | 2023-09-01 | 美商威特拉公司 | 使用介白素-2藥劑之方法 |
| US20260028384A1 (en) * | 2024-04-17 | 2026-01-29 | Visterra, Inc. | Use of il-2 variant for treating kidney transplant rejection |
| CN119638850B (zh) * | 2024-11-07 | 2026-07-31 | 浙江大学 | 双特异性细胞因子融合蛋白及其应用 |
Family Cites Families (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4908433A (en) | 1984-04-25 | 1990-03-13 | Sloan-Kettering Institute For Cancer Research | Uses of interleukin-2 |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| EP0262802A3 (en) | 1986-09-01 | 1990-01-31 | Takeda Chemical Industries, Ltd. | Medicament for the treatment or improvement of rheumatoid arthritis or systemic lupus erythematosus |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| JPH02500329A (ja) | 1987-05-21 | 1990-02-08 | クリエイテイブ・バイオマリキユールズ・インコーポレーテツド | ターゲット化多機能蛋白質 |
| US5466447A (en) | 1988-06-29 | 1995-11-14 | Amgen Inc. | Method for treating psoriasis |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| DE68927933T2 (de) | 1988-09-02 | 1997-08-14 | Dyax Corp | Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8905669D0 (en) | 1989-03-13 | 1989-04-26 | Celltech Ltd | Modified antibodies |
| WO1991000906A1 (en) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| CA2090473A1 (en) | 1990-08-29 | 1992-03-01 | Robert M. Kay | Homologous recombinatin in mammalian cells |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| CA2100671C (en) | 1991-02-27 | 1999-02-02 | James S. Huston | Serine rich peptide linkers |
| DE69233697T2 (de) | 1991-03-01 | 2008-01-24 | Dyax Corp., Cambridge | Verfahren zur Entwicklung von bindenden Mikroproteinen |
| PT100379B (pt) | 1991-04-10 | 1999-01-29 | Scripps Research Inst | Bibliotecas de receptores heterodimericos usando fagomideos |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| US5229109A (en) | 1992-04-14 | 1993-07-20 | Board Of Regents, The University Of Texas System | Low toxicity interleukin-2 analogues for use in immunotherapy |
| DE69334275D1 (de) | 1992-08-21 | 2009-05-20 | Univ Bruxelles | Immunoglobuline ohne Leichtkette |
| WO1995011922A1 (en) | 1993-10-29 | 1995-05-04 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
| DZ2788A1 (fr) | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
| US6955807B1 (en) * | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
| CA2456470A1 (en) | 2001-08-13 | 2003-02-27 | University Of Southern California | Interleukin-2 mutants with reduced toxicity |
| US20030191056A1 (en) | 2002-04-04 | 2003-10-09 | Kenneth Walker | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
| WO2005007121A2 (en) | 2003-07-18 | 2005-01-27 | Massachusetts Institute Of Technology | Mutant interleukin-2(il-2) polypeptides |
| KR20070003934A (ko) | 2004-03-05 | 2007-01-05 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템 |
| JP2009542592A (ja) | 2006-07-06 | 2009-12-03 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｉｌ−２媒介性免疫応答の有効性を高める組成物および方法 |
| WO2009061853A2 (en) | 2007-11-05 | 2009-05-14 | Massachusetts Institute Of Technology | Mutant interleukin-2 (il-2) polypeptides |
| DE102008023820A1 (de) | 2008-05-08 | 2009-11-12 | Aicuris Gmbh & Co. Kg | Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen |
| KR100873651B1 (ko) | 2008-08-21 | 2008-12-11 | 김광한 | 잔디 식재기 |
| KR101094207B1 (ko) | 2008-08-21 | 2011-12-14 | 연세대학교 산학협력단 | Ｔ１―ｔ２ 이중방식 ｍｒｉ 조영제 |
| KR100996532B1 (ko) | 2008-08-22 | 2010-11-24 | 주식회사 엠아이텍 | 탄소나노튜브 기반 바이오센서에서 링커와 스페이서를 이용한 민감도 증가 방법 |
| KR101111286B1 (ko) | 2008-08-22 | 2012-03-14 | 한국생산기술연구원 | 발포체, 이 발포체의 제조장치, 이 발포체를 이용한 발포금속의 제조방법 및 발포금속 제조장치 |
| WO2010021527A2 (ko) | 2008-08-22 | 2010-02-25 | Jung Tae Woo | 영상에 포함된 객체를 색인하는 시스템 및 방법 |
| CN102197027A (zh) | 2008-08-22 | 2011-09-21 | 株式会社Lg化学 | 用于有机电子器件的材料以及使用所述材料的有机电子器件 |
| WO2010021525A2 (en) | 2008-08-22 | 2010-02-25 | Lg Electronics Inc. | A method for processing a web service in an nrt service and a broadcast receiver |
| WO2010021520A2 (ko) | 2008-08-22 | 2010-02-25 | 엘지전자 주식회사 | 동기 채널 전송 방법 |
| WO2010085495A1 (en) | 2009-01-21 | 2010-07-29 | Amgen Inc. | Compositions and methods of treating inflammatory and autoimmune diseases |
| IT1395574B1 (it) | 2009-09-14 | 2012-10-16 | Guala Dispensing Spa | Dispositivo di erogazione |
| CN102462837B (zh) | 2010-11-19 | 2016-08-03 | 生物林格斯Ip有限公司 | 抗炎组合物 |
| CN105440123B (zh) | 2011-02-10 | 2020-10-09 | 罗切格利卡特公司 | 突变体白介素-2多肽 |
| EP3443979B2 (en) | 2011-03-11 | 2026-05-20 | Assistance Publique - Hôpitaux De Paris | IL-2 DOSAGE REGIMEN FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS |
| US9669071B2 (en) | 2011-03-11 | 2017-06-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for stimulating T lymphocytes with IL-2 |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| US9844582B2 (en) | 2012-05-22 | 2017-12-19 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents |
| US9156897B2 (en) | 2012-06-08 | 2015-10-13 | Alkermes, Inc. | Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide |
| US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
| US9580486B2 (en) | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
| PT3102595T (pt) | 2014-02-06 | 2019-01-11 | Hoffmann La Roche | Proteínas de fusão de interleucina-2 e suas utilizações |
| KR102493543B1 (ko) | 2014-07-21 | 2023-01-30 | 데리니아, 인크. | 자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 분자 |
| JP6640834B2 (ja) | 2014-08-11 | 2020-02-05 | デリニア， インコーポレイテッド | 自己免疫疾患の処置のために調節性ｔ細胞を選択的に活性化させる改変ｉｌ−２変異体 |
| IL304950A (en) | 2015-04-10 | 2023-10-01 | Amgen Inc | Interleukin for the expansion of myotonic control T-2 cells |
| AU2016246152A1 (en) | 2015-04-10 | 2017-11-02 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
| RU2611685C2 (ru) | 2015-07-20 | 2017-02-28 | Илья Владимирович Духовлинов | Гуманизированное моноклональное антитело, специфичное к синдекану-1 |
| US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| KR20240115933A (ko) | 2016-05-04 | 2024-07-26 | 암젠 인크 | T-조절 세포의 증식을 위한 인터류킨-2 뮤테인 |
| CA3032820A1 (en) | 2016-08-02 | 2018-03-22 | Visterra, Inc. | Engineered polypeptides and uses thereof |
| EP3538548A4 (en) | 2016-11-08 | 2020-08-19 | Delinia, Inc. | IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES |
| CN110325205B (zh) | 2016-12-22 | 2023-08-15 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
| CA3050601A1 (en) | 2017-02-07 | 2018-08-16 | Vib Vzm | Immune-cell targeted bispecific chimeric proteins and uses thereof |
| AU2018273914A1 (en) | 2017-05-24 | 2019-11-14 | Pandion Operations, Inc. | Targeted immunotolerance |
| US20210277085A1 (en) | 2017-05-24 | 2021-09-09 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| US20200306301A1 (en) * | 2017-07-03 | 2020-10-01 | Torque Therapeutics, Inc. | Polynucleotides Encoding Immunostimulatory Fusion Molecules and Uses Thereof |
| IL320863A (en) | 2017-10-02 | 2025-07-01 | Visterra Inc | Antibodies to CD138 and their uses |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| KR20240115352A (ko) | 2017-12-06 | 2024-07-25 | 팬디온 오퍼레이션스, 인코포레이티드 | Il-2 뮤테인 및 그 용도 |
| EP3720871A4 (en) | 2017-12-06 | 2021-09-15 | Pandion Operations, Inc. | TARGETED IMMUNOTOLERANCE |
| JP7765181B2 (ja) | 2017-12-19 | 2025-11-06 | ゼンコア インコーポレイテッド | 改変されたｉｌ－２ ｆｃ融合タンパク質 |
| US12522640B2 (en) | 2018-07-24 | 2026-01-13 | BioNTech SE | IL2 agonists |
| PH12022550165A1 (en) | 2019-07-26 | 2023-05-08 | Visterra Inc | Interleukin-2 agents and uses thereof |
| CA3203977A1 (en) | 2020-12-04 | 2022-06-09 | Visterra, Inc. | Methods of using interleukin-2 agents |
| WO2022159590A1 (en) | 2021-01-20 | 2022-07-28 | Visterra, Inc. | Interleukin-2 mutants and uses thereof |
| TW202333772A (zh) | 2021-12-01 | 2023-09-01 | 美商威特拉公司 | 使用介白素-2藥劑之方法 |
| CA3243493A1 (en) | 2022-02-11 | 2023-08-17 | Visterra, Inc. | INTERLEUKIN-2 MUTEINS FOR THE TREATMENT OF AUTOIMMUNE DISEASES |
-
2022
- 2022-12-01 TW TW111146169A patent/TW202333772A/zh unknown
- 2022-12-01 WO PCT/US2022/080728 patent/WO2023102463A1/en not_active Ceased
- 2022-12-01 CA CA3238574A patent/CA3238574A1/en active Pending
- 2022-12-01 US US18/060,725 patent/US12642840B2/en active Active
- 2022-12-01 MX MX2024006746A patent/MX2024006746A/es unknown
- 2022-12-01 EP EP22843966.7A patent/EP4440598A1/en active Pending
- 2022-12-01 JP JP2024532776A patent/JP2024543209A/ja active Pending
- 2022-12-01 AU AU2022399832A patent/AU2022399832A1/en active Pending
- 2022-12-01 CN CN202510086918.0A patent/CN120131911A/zh active Pending
- 2022-12-01 KR KR1020247021478A patent/KR20250169356A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024006746A (es) | 2024-08-09 |
| CN120131911A (zh) | 2025-06-13 |
| US20240041981A1 (en) | 2024-02-08 |
| CA3238574A1 (en) | 2023-06-08 |
| US12642840B2 (en) | 2026-06-02 |
| WO2023102463A1 (en) | 2023-06-08 |
| EP4440598A1 (en) | 2024-10-09 |
| AU2022399832A1 (en) | 2024-06-06 |
| TW202333772A (zh) | 2023-09-01 |
| JP2024543209A (ja) | 2024-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7516254B2 (ja) | Ｉｌ－１５／ｉｌ－１５ｒａヘテロ二量体ｆｃ融合タンパク質およびその使用 | |
| JP6840908B1 (ja) | エフェクター機能が除去されたＩｇＧ１ Ｆｃ変異体 | |
| TWI871272B (zh) | 具有經受限cd3結合的多重特異性多肽構築體及使用其之方法 | |
| US20240041981A1 (en) | Methods of using interleukin-2 agents | |
| EP3464367B1 (en) | Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen | |
| US20250002601A1 (en) | Multispecific antibodies binding to cd20, nkp46, cd16 and conjugated to il-2 | |
| KR20220051177A (ko) | 인터류킨-2 작용제 및 이의 용도 | |
| US20110158995A1 (en) | Multi-Specific Binding Proteins Targeting B Cell Disorders | |
| RS60664B1 (sr) | Anti-ox40 antitela i njihove upotrebe | |
| JP2023530760A (ja) | Ｈｅｒ２を標的とするアゴニストＣＤ２８抗原結合分子 | |
| KR20230127306A (ko) | NKp46 및 CD123에 결합하는 다기능성 자연살해(NK)세포 관여자 | |
| KR20230129018A (ko) | 인터류킨-2 작용제를 사용하는 방법 | |
| KR20230147072A (ko) | 인터류킨-2 돌연변이체 및 이의 용도 | |
| CN111183153A (zh) | Cd3/cd33双特异性结合分子 | |
| CN115461366A (zh) | 抗ox40抗体及其用途 | |
| CN116744946A (zh) | 用于通用细胞疗法的武装nk细胞 | |
| CN114867751B (zh) | 4-1bb和ox40结合蛋白及相关组合物和方法、抗-4-1bb抗体、抗-ox40抗体 | |
| HK40128460A (zh) | 使用白细胞介素-2药剂的方法 | |
| HK40111234A (en) | Methods of using interleukin-2 agents | |
| CN118871123A (zh) | 使用白细胞介素-2药剂的方法 | |
| RU2827796C2 (ru) | Гетеродимерные слитые белки ИЛ-15/ИЛ-15Рα - Fc и их применение | |
| HK40101528A (en) | Multispecific antibodies binding to cd20, nkp46, cd16 and conjugated to il-2 | |
| TW202615459A (zh) | 抗ｃｄ３抗體以及其相關組合物及方法 | |
| HK40085344B (en) | Anti-ox40 antibody and uses thereof | |
| HK40078517B (en) | 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| Q12 | Application published |
Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE) |